Prevalence and Phenotypic Clusters of Heart Failure with Preserved Ejection Fraction (HFpEF): A Prospective Observational Cohort Study from a Tertiary Care Centre
DOI:
https://doi.org/10.51168/sjhrafrica.v6i12.2324Keywords:
Heart failure with preserved ejection fraction, phenotypic clustering, diastolic dysfunction, echocardiography, cardiovascular epidemiologyAbstract
Background:
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases worldwide and is characterized by marked clinical, metabolic, and echocardiographic heterogeneity. This diversity has limited the effectiveness of uniform therapeutic strategies. Identification of distinct phenotypic clusters may improve risk stratification and enable individualized management.
Objectives:
To determine the prevalence of HFpEF and to identify distinct phenotypic clusters among patients presenting to a tertiary care center in eastern India.
Methods:
This was a prospective observational cohort study conducted over a 12-month period at a tertiary care teaching hospital. Consecutive adult patients diagnosed with HFpEF based on guideline-recommended criteria were enrolled. Detailed demographic, clinical, laboratory, electrocardiographic, and echocardiographic data were collected. Unsupervised cluster analysis using key clinical and echocardiographic variables was performed to identify distinct HFpEF phenotypes.
Results:
HFpEF constituted a substantial proportion of heart failure admissions during the study period. The mean age of patients was 63.4 ± 9.8 years, with a predominance of females. Hypertension (78%), diabetes mellitus (46%), and obesity (41%) were the most common comorbidities. Echocardiography demonstrated preserved systolic function with significant diastolic dysfunction, left atrial enlargement, and increased left ventricular mass. Cluster analysis identified three distinct phenotypes: a metabolic–obese phenotype, a hypertensive–atrial remodeling phenotype, and a cardiorenal–high-risk phenotype. These clusters differed significantly in metabolic burden, renal function, atrial size, diastolic indices, functional status, and hospitalization trends.
Conclusion:
HFpEF is a prevalent and heterogeneous condition in the tertiary care setting. Phenotypic clustering reveals clinically meaningful subgroups with distinct structural remodeling and disease severity, underscoring the limitations of a uniform treatment approach.
Recommendation:
Routine phenotype-based assessment of HFpEF patients should be encouraged to facilitate personalized management strategies and improve clinical outcomes.
References
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine. 2006 Jul 20;355(3):251-9.
Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal. 2011 Mar 1;32(6):670-9.
Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. New England Journal of Medicine. 2004 May 6;350(19):1953-9.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. Journal of the American College of Cardiology. 2017 Nov 14;70(20):2476-86.
Redfield MM. Heart failure with preserved ejection fraction. New England Journal of Medicine. 2016 Nov 10;375(19):1868-77.
Shah SJ. Precision medicine for heart failure with preserved ejection fraction: an overview. Journal of cardiovascular translational research. 2017 Jun;10(3):233-44.
Lam CS, Donal E, Kraigher‐Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. European journal of heart failure. 2011 Jan;13(1):18-28.
Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015 Jan 20;131(3):269-79.
Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European journal of heart failure. 2015 Sep;17(9):925-35.
Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology. 2019 Aug 6;74(5):601-12.
Savarese G, Lund LH. Global public health burden of heart failure. Cardiac failure review. 2017 Apr;3(1):7.
Gupta R, Xavier D. Hypertension: The most important non-communicable disease risk factor in India. Indian Heart Journal. 2018 Jul 1;70(4):565-72.
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology. 2017 Oct;14(10):591-602.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine. 1990 May 31;322(22):1561-6.
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American college of cardiology. 2013 Jul 23;62(4):263-71.
Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017 Jul 4;136(1):6-19.
Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. The American journal of cardiology. 2002 Dec 15;90(12):1284-9.
Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction in older adults. Tresch and Aronow's Cardiovascular Disease in the Elderly. 2019 Feb 6:422-41.
Santhanakrishnan R, Wang NA, Larson MG, Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016 Feb 2;133(5):484-92.
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. European Heart Journal. 2010 Mar 1;31(6):703-11.
Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine. 2019 Oct 24;381(17):1609-20.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner–La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N. Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine. 2021 Oct 14;385(16):1451-61.
D. Huffmann, M.A., Prabhakaran D. Heart failure: epidemiology and prevention in India. The National Medical Journal of India. 2010 Sep;23(5):283.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Praveen Kumar, Ravi Vishnu Prasad

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
















